Example Queries
Welche Indikationen gibt es für die Einnahme von Selen?
| Outcome name | Outcome specification | Results after intervention | Overall RoB judgment | |
|---|---|---|---|---|
| Asfour et al. (2006): Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients | Toxicity Ejection fraction | Infectionrate after chemotherapy Cardiac ejection fraction | NA NA | high risk high risk |
| Büntzel et al. (2010): Limited effects of selenium in the prevention of radiation-associated toxicities - results of a randomized study in head neck cancer patients | Toxicity | Grade of radiotherapy-associated side effects: Xerostomia, stomatitis, ageusia, and dysphagia | No significant differences; overall number of serious adverse events, not significantly different: intervention arm 23x and control arm 22x (p=0.476) | some concerns |
| Büntzel et al. (2010): Selenium Substitution During Radiotherapy of Solid Tumours - Laboratory Data from Two Observation Studies in Gynaecological and Head and Neck Cancer Patients | Selenium level | Serum concentration and whole blood concentration | At 6 weeks after irradiation no significant differences; Significant differences in selenium concentrations (serum and blood) at the end of radiotherapy (p<0.0001) | NA |
| Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial | RFS (Recurrence-Free Survival) PFS (Progression-Free Survival) Selenium level | NA NA Measured at baseline and after 3 years | ITT: intervention arm n=43 (28%; 95% CI: 0.21, 0.35) and placebo arm n=45 (32%; 95% CI: 0.24, 0.40); HR: 0.85 (95% CI: 0.56, 1.29); p=0.44, not significant
PP: (all participants remaining in the study after 3 months): intervention arm n=42 and placebo arm n=39 (28%; 95% CI: 0.20, 0.35); HR: 0.96 (95% CI: 0.62, 1.48)); p=0.85, not significant No influence of age, gender, nicotine consumption, stage, selenium concentration at baseline and hospital Significant difference in selenium concentration after 3 years (n=67 (55%)): 187.6 mg/dl ± 57.7 mg/dl intervention arm vs. 88.9 mg/dl ± 22.2 mg/dl placebo arm; p=0.00 | some concerns some concerns some concerns |
| Jahangard-Rafsanjani et al. (2013): The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial | Haematological indices Length of hospital stay Incidence of acute GVHD (Graft-Versus-Host Disease) Mortality rate Non-haematological indices Selenium level Mucositis Fever | Neutrophil and platelet engraftment time (the time point after transplantation at which a patient can maintain a sustained ANC of 4500 cells/mm3 and a sustained platelet count of at least 20 000/mm3 lasting 3 consecutive days without transfusions during hospital stay) NA Graft-versus-host disease is a condition where the donated stem cells (graft) attack the recipient's body (host) At 3 months Serum creatinine level and blood urea nitrogen test for renal function assessment and aspartate aminotransferase and alanine transaminase for liver function assessment, recorded daily NA Oral Mucositis Duration of fever | NA No difference between selenium arm (26.92±6.26 days) and placebo arm (25.81±4.33 days); p=0.38 Overall: No difference between the arms; p= 0.35 No difference between the arms; p= 0.69 Overall: No difference between arms for increase in serum creatinine; p=0.31 or increase in aspartate aminotransferase and alanine transaminase: p=0.62 Significant difference in mean serum selenium level between two arms at 14 days after transplantation (8.34 mcg/dL in the selenium arm vs 7.36 mcg/dL in the placebo arm), p=0.018 Overall: Cumulative incidence (grade 1-4) comparable in both selenium arm (83.8%) and placebo arm (81.1%); p=0.76; grade 3-4 mucositis significantly lower in selenium arm (10.8%) compared to placebo arm (35.1%); p=0.013 (grade 4: 2x in placebo arm, 0x in selenium arm)
NA | some concerns some concerns some concerns some concerns some concerns some concerns high risk some concerns |
| Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 | OS (Overall Survival) Toxicity Selenium level DFS (Disease-Free Survival) | 5-year OS NA NA DFS Randomization until secondary tumors or recurrence and 5-year DFS | Intervention arm: 76.8% (SE, 1.6%) vs. placebo arm: 79.9% (SE, 2.1%); p=0.154
N=83 secondary lung tumors; Rate intervention arm: 1.91 per 100 persons per year vs. 1.36 in placebo arm; p=ns
| low risk low risk low risk low risk |
| Laali et al. (2020): Effect of Selenium on Incidence and Severity of Mucositis during Radiotherapy in Patients with Head and Neck Cancer | Selenium level Mucositis | NA Inflammation of the oral mucosa (mucositis) due to radiotherapy | At the end of radiation (after 7 weeks) there was no difference in the mean serum selenium level between the selenium arm and placebo arm (p=0.24)
Based on the selenium level before radiation, developing severe oral mucositis was statistically significant postponed in patients who had selenium levels ≥ 65 mcg/L (p=0.04)
| NA high risk |
| Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck | Mucositis Tumor response PFS (Progression-Free Survival) OS (Overall Survival) Quality of life Toxicity | Grade 3 or 4 Complete response rate (CR) NA NA Measured with EORTC C-30 Version 3 and EORTC QLQ - H&N35 Other treatment-associated side effects such as xerostomia, renal impairment, hearing dysfunction, and myelosuppression | Overall: No significant differences between arms (grade 3 intervention arm 2x, placebo arm 3x, no grade 4) Only one patient from the intervention arm did not reach CR and died After 12 months: No significant differences between arms After 12 months: No significant differences between arms No significant difference for week 6-8 post-treatment and Follow-up within a year Overall:
| some concerns low risk low risk low risk some concerns some concerns |
| Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology | Selenium level Toxicity Performance Status Quality of life DFS (Disease-Free Survival) OS (Overall Survival) | Efficiancy of supplementation Diarrhea NA NA NA NA | After 6 weeks post radiotherapy, levels between arms were comparable Overall incidence of grade 2 diarrhea: intervention arm 20.5% vs. control arm 44.5% (p = 0.04) No difference between arms No difference between arms Median follow-up of 49 months (range, 0-75): 5-year disease free survival in the intervention arm was 80.1% vs. 83.2% in the control arm, no significant difference; p = 0.74 Median follow-up of 51 months (range 6-75): 5-year overall survival in the intervention arm was 91.9% vs. 83.1% in the control arm, no significant difference; p = 0.34 | some concerns some concerns some concerns some concerns some concerns some concerns |
| Muecke et al. (2013): Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology-a subgroup analysis of a multicenter, phase III trial | Toxicity | Diarrhea | NA | some concerns |
| Muecke et al. (2014): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization | DFS (Disease-Free Survival) OS (Overall Survival) | 10-year disease-free survival 10-year overall survival | 10-year disease-free survival intervention arm 80.1% vs. control arm 83.2%; not significant; p = 0.65 10-year overall survival intervention arm 55.3% vs. control arm 42.7%; not significant; p = 0.09 | high risk high risk |
| Stratton et al. (2010): Oral Selenium Supplementation Has No Effect on Prostate- Specific Antigen Velocity in Men Undergoing Active Surveillance for Localized Prostate Cancer | PSA level (Prostate-Specific Antigen) | Change over 5 years | After 5 years: selenium arms not significantly different to placebo arm (p=0.32 and p=0.61) or to each other Subgroup of high-selenium arm with high selenium value at baseline shows higher PSA values than placebo arm (p=0.018) | some concerns |
Hilft Vitamin C gegen Fatigue?
| Results during intervention | Results after intervention | Overall RoB judgment | |
|---|---|---|---|
| Jeon et al. (2016): Effect of intravenous high dose Vitamin C on postoperative pain and morphine use after laparoscopic colectomy: A randomized controlled trial | NA NA NA ? | Estimated mean (SD) from graphic:
2, 6 and 24h post-op: at rest significantly lower in intervention compared to placebo; p's<0.05 (no values reported, only graphs) While coughing: no significant difference at any time point; p's>0.05 Frequency as Mean(SD): Intervention: 0.8(0.8) Placebo: 1.4(1.0) | ? ? ? ? |
Welche Evidenz gibt es für Vitamin C hochdosiert?
| Outcome name | Results after intervention | Dosage and regime | Overall RoB judgment | |
|---|---|---|---|---|
| Chung et al. (2016): Randomized Trial of Vitamin C/E Complex for Prevention of Radiation- Induced Xerostomia in Patients with Head and Neck Cancer | Xerostomia OS (Overall Survival) DFS (Disease-Free Survival) | T0: before radiotherapy,
T1: 1 month post-radiotherapy, T2: 6 months post-radiotherapy Xerostomia questionnaire (mean (SD), no group comparison reported) Intervention arm T0: 5.4 (4.3), T1: 8.1 (4.2), T2: 5.4 (4.0) T0-T1: p = 0.02, T1-T2: p = 0.007 Placebo arm T0: 4.6 (3.8), T1: 7.0 (4.5), T2: 7.0 (4.6) T0-T1: p = 0.06 T1-T2: p = 0.97 Xerostomia score (no group comparison reported) Intervention arm T0: 2.8 (2.3), T1: 5.0 (2.8), T2: 3.7 (3.9) T0-T1: p = 0.004, T1-T2: p = 0.008 Placebo arm T0: 1.7 (1.4), T1: 3.9 (2.4), T2: 3.3 (2.3) T0-T1: p = 0.004, T1-T2: p = 0.47 Salivary scintigraphy
No group difference for maximum accumulation, or ejection fraction at T1 or T2 (p=0.86, p=0.15; p=0.57, p=0.68),
Intervention arm showed better values before (p=0.01) and after stimulation (p=0.009) compared to placebo arm at T1 No significant differences between arms (p = 0.75) | 100 IU vitamin E + 500mg vitamin C, orally, 2x daily, duration: 1 week prior to radiotherapy until 1 month after radiotherapy (average intervention period: 3 months) Placebo pill, orally, 2x daily, duration: 1 week prior to radiotherapy until 1 month after radiotherapy (average intervention period: 3 months) | ? ? ? |
| Jeon et al. (2016): Effect of intravenous high dose Vitamin C on postoperative pain and morphine use after laparoscopic colectomy: A randomized controlled trial | Pain Additional medication Fatigue Additional medication | Estimated mean (SD) from graphic:
2, 6 and 24h post-op: at rest significantly lower in intervention compared to placebo; p's<0.05 (no values reported, only graphs) While coughing: no significant difference at any time point; p's>0.05 Frequency as Mean(SD): Intervention: 0.8(0.8) Placebo: 1.4(1.0) | Intravenous, 30 minutes 50mg/kg (ascorbic acid 10 g/20 mL) mixed with normal saline for a total injection volume of 50 mL; intravenous, 30 minutes | ? ? ? ? |
| Liu et al. (2010): Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial | Salivary gland function Salivary gland function Salivary gland function Salivary gland function | No data available NA NA NA | 100 mg every 4 h in the daytime over 6 d 100 mg every 4 h in the daytime over 6 d 100 mg every 4 h in the daytime over 6 d 100 mg every 4 h in the daytime over 6 d | ? ? ? ? |
Welche Nebenwirkungen hat Curcumin?
Hilft Curcumin gegen Übelkeit?
Keine Ergebnisse gefunden.
Verbessert Vitamin D die Osteoporose?
Keine Ergebnisse gefunden.
In welcher Dosis sollte Vitamin D eingenommen werden?
| Dosage and regime | |
|---|---|
| Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial | Two capsules of vitamin D3 (total 1,200 IU/day), for 12 months Two capsule form and identical in appearance and taste, containing sesame oil, gelatin derived from swine, and glycerin, for 12 months |
| Antunac et al. (2018): Vitamin D Supplementation and Survival in Metastatic Colorectal Cancer | Cholecalciferol 2000 IU daily, for 2 years or until death, whichever came first Only standard chemotherapy |
| Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer | Supplied by Genzyme as 2.5 μg soft gel capsules,10 μg (i.e., four capsules of 2.5 μg) of doxercalciferol orally each day of the chemotherapy cycles before breakfast and at the same time,
Duration: for 1-12 cycles of chemotherapy (each cycle: 28 days), median duration: 6 cycles |
| Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators | DN-101 (45 μg) orally (high concentration formulation of calcitriol), weekly for 3 consecutive weeks of a 4-week cycle Placebo orally (high concentration formulation of calcitriol), weekly for 3 consecutive weeks of a 4-week cycle |
| Brown et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial | A loading dose of 8000 IU/d of vitamin D3 (two 4000 IU capsules) for cycle 1 followed by 4000 IU/d for subsequent cycles 400 IU/d of vitamin D3 during all cycles (one 400 IU capsule plus 1 placebo capsule during cycle 1) |
| ... further results | |
Für/gegen was ist die Einnahme von Aloe empfehlenswert?
Hilft Aloe bei Mukositis?
| Results after intervention | Overall RoB judgment | |
|---|---|---|
| Jahangard-Rafsanjani et al. (2013): The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial | NA No difference between selenium arm (26.92±6.26 days) and placebo arm (25.81±4.33 days); p=0.38 Overall: No difference between the arms; p= 0.35 No difference between the arms; p= 0.69 Overall: No difference between arms for increase in serum creatinine; p=0.31 or increase in aspartate aminotransferase and alanine transaminase: p=0.62 Significant difference in mean serum selenium level between two arms at 14 days after transplantation (8.34 mcg/dL in the selenium arm vs 7.36 mcg/dL in the placebo arm), p=0.018 Overall: Cumulative incidence (grade 1-4) comparable in both selenium arm (83.8%) and placebo arm (81.1%); p=0.76; grade 3-4 mucositis significantly lower in selenium arm (10.8%) compared to placebo arm (35.1%); p=0.013 (grade 4: 2x in placebo arm, 0x in selenium arm)
NA | some concerns some concerns some concerns some concerns some concerns some concerns high risk some concerns |
| Laali et al. (2020): Effect of Selenium on Incidence and Severity of Mucositis during Radiotherapy in Patients with Head and Neck Cancer | At the end of radiation (after 7 weeks) there was no difference in the mean serum selenium level between the selenium arm and placebo arm (p=0.24)
Based on the selenium level before radiation, developing severe oral mucositis was statistically significant postponed in patients who had selenium levels ≥ 65 mcg/L (p=0.04)
| NA high risk |
| Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck | Overall: No significant differences between arms (grade 3 intervention arm 2x, placebo arm 3x, no grade 4) Only one patient from the intervention arm did not reach CR and died After 12 months: No significant differences between arms After 12 months: No significant differences between arms No significant difference for week 6-8 post-treatment and Follow-up within a year Overall:
| some concerns low risk low risk low risk some concerns some concerns |
Schützt Aloe vor Hautentzündungen?
In welcher Dosis sollte man Ingwer bei Übelkeit einsetzen?
| Outcome name | Dosage and regime | |
|---|---|---|
| Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy | Nausea Vomiting | Daily dose 2x2 ginger capsules (250mg ginger powder each), every 12h for 3 days over 3 cycles, start not specified Daily dose 2x2 capsules, every 12h for 3 days over 3 cycles, start not specified |
| Fahimi et al. (2011): Evaluating the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens | Nausea Vomiting | Four capsules of powdered ginger (Zintoma®, Gol Daru) daily (each capsule contained 250 mg of ginger) Four capsules of placebo (lactose) |
| Lua et al. (2015): Effects of inhaled ginger aromatherapy on chemotherapy-induced nausea and vomiting and health-related quality of life in women with breast cancer | Nausea Quality of life Unspecified effects | Antiemetics + bottle with 2 drops of ginger oil
Glass pendant (in the form of a small flask), to be hung approx. 20 cm from the nose, the bottle was held directly under the nose and inhaled deeply at least 3 times a day for 2 minutes each time Start: Day 1 of chemotherapy |
| Panahi et al. (2012): Effect of Ginger on Acute and Delayed Chemotherapy-Induced Nausea and Vomiting: A Pilot, Randomized, Open-Label Clinical Trial | Nausea and Vomiting Nausea and Vomiting Nausea and Vomiting | Daily dose 3x0.5g
Every 8h, starting 30min after chemotherapy Every 8h, starting 30min after Chemotherapy |
| Ryan et al. (2011): Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients | Nausea Nausea Quality of life Vomiting | 250mg 2x3 ginger capsules (liquid extract from ginger root in virgin olive oil + excipients, 1.5g ginger daily)
1.5g daily 2x3 placebo capsules |
| Sontakke et al. (2003): Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: A randomized, cross-over, double blind study | Nausea Vomiting Vomiting Toxicity | Two capsules, each containing 500 mg of gin- ger powder, orally, 2 ml of normal saline IV, 20 min prior to chemotherapy. Two capsules of ginger were repeated after 6 h of cancer chemotherapy. 2 capsules of lactulose orally and injection metoclopramide 20 mg IV, 20 min prior to chemotherapy. Two capsules of 5 mg metoclopramide each, orally after 6 h 2 capsules of lactulose orally and injection ondansetron 4 mg IV, 20 min prior to chemotherapy and two capsules of ondansetron, 2 mg each, orally after 6 h. |
| Uthaipaisanwong et al. (2020): Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study | Nausea Nausea Vomiting Toxicity | Daily dose 4x500mg before meals and one in the evening from day 1 to day 5 of chemotherapy
+ standard antiemetic medication included 20 mg of dexamethasone, 8 mg of ondansetron, and 50 mg of ranitidine which were injected 30 min before chemotherapy administration; if necessary 50mg dimenhydrinate before chemotherapy and 5 days at home |
| Zick et al. (2008): Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting | Unspecified effects Nausea and Vomiting Nausea and Vomiting Toxicity | 8 capsules daily 1.0-g ginger dose, - Each capsule contained 250 mg dry extract of ginger root [10:1 (v/v) extraction solvent (ethanol 50%)/root] standard- ized to 15 mg (5%) of total gingerols
- four capsules ginger and four capsules placebo daily |